-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome

Sponsor: Gilead Sciences, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events
Friday, December 8, 2023: 3:00 PM-6:00 PM
Room 6DE (San Diego Convention Center)
Chair:
Amer M. Zeidan, MBBS, MHS, Yale University
Disclosures:
Zeidan: Shattuck Labs: Research Funding; Astex: Research Funding; BioCryst: Consultancy, Honoraria; Kura: Consultancy, Honoraria; Geron: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Syros: Consultancy, Honoraria; Lox Oncology: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; ALX Oncology: Consultancy, Honoraria; Chiesi: Consultancy, Honoraria; Taiho: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Syndax: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Celgene/BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Orum: Consultancy, Honoraria; Notable: Consultancy, Honoraria; BeyondSpring: Consultancy, Honoraria; Otsuka: Consultancy, Honoraria; Boehringer-Ingelheim: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Mendus: Consultancy, Honoraria; Foran: Consultancy, Research Funding; Tyme: Consultancy, Honoraria; Schrödinger: Consultancy, Honoraria; Zentalis: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Ionis: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Novartis: Consultancy, Honoraria.
Speakers:
Rami S. Komrokji, MD, Moffitt Cancer Center and Douglas Burgoyne, PharmD, FAMCP, University of Utah
Disclosures:
Komrokji: Geron: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees; Rigel, Taiho, DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie, CTI biopharma, Jazz, Pharma Essentia, Servio: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.
On Demand program will be available here December 28, 2023.

Join expert MDS faculty as they take a deep dive into the latest clinical evidence and applications for MDS treatment and management. Informed by provider surveys designed to assess knowledge and confidence gaps in MDS testing, risk assessment, and differentiating new and emerging therapies, as well as barriers to integrating the latest evidence into clinical practice, this satellite symposium will support MDS care teams in examining the latest evidence, differentiating new and emerging therapies for MDS, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Additionally, through partnership with the MDS Foundation, a patient vignette will be incorporated into the symposium highlighting disease burden and real-world experiences in care to deepen the impact of the education and provide a basis for discussion and strategy to enhance patient-centered care.